Nanjing Leads Biolabs (HKG:9887) posted a loss attributable to owners of 166.4 million yuan for the first half of 2025, compared with a 180.4 million yuan loss a year earlier, according to an Aug. 29 Hong Kong bourse filing.
Shares of the clinical-stage biotech were up nearly 2% in Monday afternoon trade.
Loss per share was 1.06 yuan, compared with 1.22 yuan in the same period last year.
It reported no nil revenue for the reporting period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.